US EditionAstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
UNITED STATES, JUL 21 – AstraZeneca plans to create tens of thousands of jobs through $50 billion investment in US manufacturing and research, aiming to boost domestic pharmaceutical production by 2030.
- On July 21, 2025, AstraZeneca announced plans to invest $50 billion by 2030 to expand manufacturing and research in the U.S., including a new Virginia facility.
- This large investment follows sustained U.S. tariffs and political pressure from President Trump urging pharmaceutical companies to increase domestic production, as explained by Commerce Secretary Howard Lutnick.
- The Virginia facility will be AstraZeneca's largest manufacturing investment worldwide, producing active ingredients for weight management and cholesterol medicines, while expansions will cover five other U.S. states.
- AstraZeneca CEO Pascal Soriot stated that the funding initiative aligns with the company’s target to generate $80 billion in yearly sales by 2030, with approximately 50% expected to originate from the U.S. Meanwhile, Commerce Secretary Howard Lutnick described the investment as a landmark move that will create tens of thousands of employment opportunities.
- The investment signals AstraZeneca's prioritization of the U.S. market, reacting to tariff policies and industry pressures, and follows similar commitments by other top drugmakers to boost domestic manufacturing and R&D.
66 Articles
66 Articles
AstraZeneca to Invest $50 Billion in US as Tariff Threat Looms
AstraZeneca said on Tuesday it plans to invest $50 billion in the United States by 2030, funding a new multibillion-dollar manufacturing facility in Virginia and expanding research, development, and cell therapy operations in Maryland, Massachusetts, California, Indiana, and Texas. The Virginia site will manufacture drug substances for weight management and metabolic treatments, including oral GLP-1 drugs, baxdrostat, oral PCSK9 inhibitors, and …
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.
British pharmaceutical company AstraZeneca plans to invest $50 billion (almost €43 billion) in the United States over the next five years. The money will be used to…
Coverage Details
Bias Distribution
- 49% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
